Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra 11:41:26 2024-05-23 am EDT After market 03:58:22 pm
169 EUR +0.33% Intraday chart for Merck KGaA 168.5 -0.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
MERCK KGAA : Receives a Buy rating from UBS ZD
Merck KGaA: acquisition of U.S.-based Mirus Bio CF
News Highlights : Top Company News of the Day - Thursday at 3 AM ET DJ
News Highlights : Top Company News of the Day - Thursday at 1 AM ET DJ
Merck KGaA Buys Mirus Bio for $600 Million DJ
Merck to Buy Mirus Bio for $600 Million MT
News Highlights : Top Company News of the Day - Wednesday at 11 PM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 9 PM ET DJ
MERCK KGAA : DZ Bank gives a Buy rating ZD
MERCK KGAA : Gets a Buy rating from Barclays ZD
EU GDP Estimates, Rosy Spring Forecast Prop Up German Stocks MT
MERCK : Electronics came as a big surprise Alphavalue
Transcript : Merck KGaA, Q1 2024 Earnings Call, May 15, 2024
UBS rates Merck KGaA a 'Buy' - Target 186 euros DP
Upbeat earnings lift European shares to record high ahead of US inflation data RE
MERCK KGAA : UBS maintains a Buy rating ZD
Positive quarterly report pushes Merck KGaA to annual high DP
Merck KGaA: 13% decline in quarterly adjusted EPS CF
Industrials lift European shares to record high ahead of US inflation data RE
Merck KGaA Posts Lower Q1 Attributable Profit, Net Sales MT
Merck KGaA's Q1 adjusted profit declines less than feared RE
Merck KGaA Confirms Outlook After Drop in Sales, Earnings DJ
Merck KGaA Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Cinven to explore $3 billion sale of software maker Jaggaer, sources say RE
MERCK KGAA : UBS reiterates its Buy rating ZD
Chart Merck KGaA
More charts
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
168.5 EUR
Average target price
182.9 EUR
Spread / Average Target
+8.57%
Consensus
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck KGaA
  5. Biocartis, Merck KGaA Expand Cancer Biomarker Testing Collaboration into MENA Region